Last updated: September 4, 2026

Estradiol cypionate and medroxyprogesterone acetate are mature, low-growth hormonal products with largely expired primary intellectual property. Estradiol cypionate injection is a niche estrogen replacement product. Medroxyprogesterone acetate has a larger commercial base because it is used in contraception, endometrial protection, oncology, and other hormone-related indications. Revenue is concentrated in generic and legacy products, while branded sales have limited strategic value relative to newer long-acting contraceptives, transdermal estrogen products, and oral or intrauterine progestogen therapies.

Neither molecule has a meaningful remaining composition-of-matter patent barrier in the United States. Commercial performance depends on manufacturing reliability, payer pricing, supply continuity, formulation differentiation, and clinical preferences rather than patent exclusivity.

What are estradiol cypionate and medroxyprogesterone acetate used for?

Estradiol cypionate is a long-acting injectable ester of estradiol. In the United States, Pfizer’s Depo-Estradiol injection is labeled for estrogen-deficiency symptoms associated with menopause and for selected hypoestrogenic conditions. The product is administered intramuscularly and is not a first-line commercial choice for most current menopausal hormone-therapy patients, who often receive oral or transdermal estradiol.

Medroxyprogesterone acetate, commonly abbreviated MPA, is a synthetic progestin. Its principal commercial applications include:

Depot medroxyprogesterone acetate, or DMPA, for contraception.
Oral therapy under the Provera brand and generic equivalents.
Prevention of endometrial hyperplasia in women receiving unopposed estrogen.
Treatment of recurrent or metastatic endometrial, renal, and breast cancers in selected settings.
Management of abnormal uterine bleeding and other progestin-responsive conditions.

There is no widely marketed FDA-approved fixed-dose combination product containing estradiol cypionate and medroxyprogesterone acetate. The two agents may be used within broader hormone-management strategies, but they are commercially separate products.

How large is the market for estradiol cypionate and medroxyprogesterone acetate?

The combined market is difficult to measure because the products are sold across separate therapeutic categories and public company filings do not usually report them as individual revenue lines.

Product or category	Principal U.S. products	Market structure	Commercial outlook
Estradiol cypionate injection	Depo-Estradiol and limited equivalents	Small, mature branded or limited-generic market	Flat to declining
MPA injectable contraception	Depo-Provera CI, generic DMPA injection	Branded legacy product plus generic competition	Stable demand, pricing pressure
MPA subcutaneous contraception	Depo-subQ Provera 104 and related presentations	Smaller delivery-specific market	Depends on access and self-administration
Oral MPA	Provera and multiple generics	Highly genericized	Low unit pricing, durable clinical use
MPA oncology products	Generic oral and injectable products	Institutional and specialty demand	Low growth, indication-specific
Estradiol plus progestin therapy	Mostly separate or alternative formulations	Competitive menopause market	Shift toward transdermal and oral combinations

The largest addressable segment is MPA-based contraception. DMPA remains an important injectable contraceptive because it provides approximately three months of pregnancy prevention per administration and does not require daily adherence. Estradiol cypionate has a much smaller market because injectable estrogen is less commonly selected than patches, gels, creams, and oral estrogen.

Global demand is more significant than U.S. commercial revenue for DMPA. Public-sector procurement, reproductive-health programs, and international donor channels can materially affect volume, while unit prices remain low. The World Health Organization recognizes DMPA as an established contraceptive option but also emphasizes informed choice and consideration of alternative methods.[1]

What is the FDA regulatory status of estradiol cypionate and medroxyprogesterone acetate?

Both active ingredients have long-standing FDA approval histories and are no longer dependent on new-drug exclusivity.

Product	FDA status	Key regulatory point
Depo-Estradiol injection	Approved prescription drug	Legacy estrogen product with mature labeling
Depo-Provera CI	Approved prescription contraceptive	Depot MPA injection with established efficacy and safety labeling
Depo-subQ Provera 104	Approved prescription contraceptive	Lower-dose subcutaneous MPA presentation
Generic MPA injection	Approved through abbreviated applications where applicable	Competes primarily on price and supply
Generic oral MPA	Approved through abbreviated applications	Multiple suppliers and low unit economics

The FDA label for Depo-Provera CI identifies the product as medroxyprogesterone acetate injectable suspension at 150 mg/mL for intramuscular use. Depo-subQ Provera 104 uses a lower dose administered subcutaneously.[2,3]

The key regulatory risks are safety and labeling risks rather than approval barriers. MPA products carry warnings and precautions related to bone mineral density, thromboembolic and cardiovascular risk factors, breast and reproductive-system effects, and prolonged return to fertility after discontinuation. Estrogen products carry class warnings involving cardiovascular events, malignancy, and other risks described in the applicable labeling.[2,4]

When do estradiol cypionate and medroxyprogesterone acetate lose exclusivity?

The principal patent and regulatory exclusivity periods for these active ingredients expired decades ago. No commercially significant U.S. exclusivity barrier is expected to block generic entry for the conventional injectable or oral products.

Estradiol cypionate exclusivity

Estradiol cypionate was introduced as an older injectable estrogen product. Its underlying active-ingredient and conventional formulation protection is historical rather than current. A competitor can generally pursue an FDA pathway based on the relevant reference product, subject to product-specific requirements and manufacturing capability.

Medroxyprogesterone acetate exclusivity

MPA has been marketed for many decades in oral and injectable forms. The original composition-of-matter and early formulation protections have expired. The remaining commercial value is associated with:

Brand recognition.
FDA-approved indications.
Manufacturing know-how.
Sterile injectable production.
Distribution contracts.
Device and presentation design.
Regulatory compliance and supply reliability.

The Orange Book remains the relevant source for current listed patents and regulatory exclusivity. For legacy products, listed patents may be absent, expired, or immaterial to an entrant’s commercial decision.[5]

What patents protect estradiol cypionate and medroxyprogesterone acetate?

No active U.S. composition-of-matter patent is expected to provide meaningful protection for either molecule. Any relevant protection is more likely to involve a specific formulation, delivery system, manufacturing process, or newly developed combination.

Formulation patents

Potential formulation claims could cover:

Injectable suspension particle size.
Solvent or vehicle composition.
Preservative systems.
Sterility and container-closure systems.
Subcutaneous delivery parameters.
Prefilled syringes or autoinjector presentations.
Extended-release pharmacokinetic profiles.

These claims would not automatically protect the underlying molecule. Their enforceability would depend on claim scope, FDA product equivalence, and whether a competing product practices the patented formulation.

Method-of-use patents

Method-of-use patents could target narrow clinical applications, dosing schedules, or patient populations. Their commercial effect is limited when the drug has multiple established uses and generic manufacturers can pursue non-infringing labeling. For MPA, the broad contraceptive, oncology, and gynecologic indications are mature and unlikely to support broad new-use exclusivity without a materially differentiated clinical application.

Manufacturing and supply barriers

Sterile injectable manufacturing is the most credible non-patent barrier. A generic supplier must demonstrate control over:

Sterility assurance.
Suspension uniformity.
Particle-size distribution.
Dose consistency.
Container compatibility.
Stability over the labeled shelf life.
Scale-up and process validation.

These requirements can limit the number of reliable suppliers even when patents have expired. The result is a market in which legal entry is easy relative to operational entry.

Are there Paragraph IV challenges for these products?

Paragraph IV litigation is unlikely to be a major current market event for the legacy products because the principal patent estate has expired or has limited blocking value. Generic applicants may still use abbreviated new drug applications, but a current Paragraph IV challenge would have limited commercial significance unless a new formulation or device patent were listed in the Orange Book.

The more relevant regulatory pathway is ordinary generic competition under the Hatch-Waxman framework. A generic applicant must show pharmaceutical equivalence and bioequivalence, or satisfy FDA requirements for the applicable complex injectable product. For depot injections, formulation and pharmacokinetic comparability can be more demanding than for simple immediate-release tablets.

Potential litigation could arise over:

A newly listed formulation patent.
A device or administration patent.
Manufacturing-process claims.
False patent-certification allegations.
Product labeling or trade-dress disputes.
Regulatory exclusivity associated with a new dosage form.

No broad, active patent litigation is central to the commercial outlook of conventional estradiol cypionate or MPA products based on their mature regulatory position.

What is the competitive landscape for MPA contraception?

DMPA competes against methods with different durations, prices, and user requirements.

Competitor	Typical duration	Competitive advantage over DMPA	Competitive weakness
Levonorgestrel intrauterine systems	3 to 8 years, depending on product	High efficacy and long duration	Insertion procedure and upfront access barriers
Etonogestrel implant	About 3 years	Long duration and reversibility	Insertion and removal procedure
Combined oral contraceptives	Daily	Familiarity and broad product choice	Adherence burden
Progestin-only pills	Daily	Estrogen-free option	Daily adherence
Transdermal and vaginal methods	Weekly or monthly	User-controlled administration	Regular replacement
DMPA injection	About 13 weeks	Private, infrequent dosing	Clinic visit, delayed return to fertility, bone-density concerns

DMPA’s commercial position is strongest where users prioritize discretion, low administration frequency, and avoidance of daily dosing. Its position is weaker among patients who prefer rapid fertility return, long-acting reversible contraception, or self-administered options.

The subcutaneous presentation provides a potential commercial advantage because it can support self-injection programs in appropriate settings. Its lower dose and delivery system differentiate it from the traditional 150-mg intramuscular presentation, but that differentiation does not create a broad patent moat.

How does estradiol cypionate compare with modern estrogen products?

Estradiol cypionate injection competes with several dosage forms that are easier to titrate and more consistent with current prescribing preferences.

Product class	Main advantage	Market effect on estradiol cypionate
Oral estradiol	Low cost and broad availability	Captures routine hormone-therapy demand
Transdermal patches	Lower hepatic first-pass exposure	Preferred for some patients with cardiovascular or metabolic risk factors
Estradiol gels and sprays	Flexible dosing and nonoral delivery	Expand alternatives to injection
Vaginal estrogen	Local symptom control with lower systemic exposure	Reduces need for systemic injectable estrogen
Estradiol valerate or cypionate injections	Infrequent administration	Retains niche demand where injection is preferred

The injectable form can have value in gender-affirming hormone therapy and selected specialty practices, but product choice varies by prescriber, dose availability, pharmacy supply, and route-of-administration preference. The commercial opportunity is limited by the availability of lower-cost alternatives and the absence of a large, differentiated evidence package for estradiol cypionate injection.

What is the financial trajectory for these products?

The financial trajectory is mature and bifurcated.

Estradiol cypionate

Estradiol cypionate is likely to remain a small-revenue product with limited growth. Its value is supported by recurring demand from a narrow patient population and by the difficulty of replacing every injectable estrogen use with another dosage form. Volume can be affected by shortages, distributor stocking decisions, and the number of manufacturers willing to maintain a low-volume sterile injectable line.

Expected financial pattern:

Low absolute revenue.
Limited volume growth.
Higher sensitivity to supply interruptions.
Potential price volatility if only one or a few suppliers remain.
Limited justification for major clinical-development investment.

Medroxyprogesterone acetate

MPA has a more durable revenue base because it is used across several indications and dosage forms. The injectable contraceptive franchise has greater unit and public-health relevance than estradiol cypionate, but generic competition constrains price.

Expected financial pattern:

Stable or gradually declining branded revenue.
Persistent high-volume generic demand.
Low average selling prices in oral products.
Better margin potential in differentiated injectable presentations.
Continued institutional and international demand.
Limited upside without a new delivery system or expanded access program.

Pfizer does not generally report Depo-Provera, Depo-subQ Provera 104, and Depo-Estradiol as separately disclosed major revenue categories in its consolidated public filings. This prevents a reliable product-level revenue series from public annual reports.[6] Market estimates from commercial prescription databases may also understate public-sector and international DMPA volume.

What licensing deals affect estradiol cypionate or medroxyprogesterone acetate?

No major recent licensing transaction is central to the commercial outlook of the conventional molecules. The original products are legacy assets, and their value is more likely to move through:

Generic supply agreements.
Regional marketing rights.
Contract manufacturing arrangements.
Public-sector procurement contracts.
Authorized-generic or distributor relationships.
Product divestitures involving mature portfolios.

A licensing transaction involving either molecule would probably be driven by manufacturing access, geographic rights, or a differentiated delivery technology rather than by control of an unexpired core patent.

What generic entry risks exist for these products?

Generic entry risk is high in legal terms and moderate in operational terms.

For oral MPA, generic substitution is well established. Entry can rapidly reduce price and branded share. For injectable MPA, entry is more constrained by sterile manufacturing, suspension technology, regulatory review, and supply-chain execution. Estradiol cypionate faces a smaller market, which can deter entrants because development costs may not be recovered through large volume.

The principal risks to an incumbent are:

New generic approvals.
Loss of preferred formulary status.
Tender-price compression.
Manufacturing interruptions.
Substitution by newer contraceptive or estrogen delivery systems.
Safety-driven prescribing changes.
Reduced clinic administration for injectable products.

What geographic markets offer the strongest growth potential?

The strongest volume opportunity for MPA is outside the U.S., particularly in public-sector contraception programs and markets where injectable contraception is widely accepted. Revenue quality depends on procurement pricing and donor funding, so high volume does not necessarily produce high margins.

Estradiol cypionate has a narrower geographic opportunity. Demand is concentrated in countries with established access to injectable hormone therapy and specialty prescribing channels. Transdermal and oral alternatives limit expansion in higher-income markets.

For both products, geographic growth is more likely to come from distribution and access expansion than from premium pricing.

Key Takeaways

Estradiol cypionate is a niche, mature injectable estrogen product with limited revenue growth.
Medroxyprogesterone acetate has a larger and more durable market because it spans contraception, gynecology, oncology, and oral therapy.
Core patent and regulatory exclusivity has expired for both molecules.
Conventional products face high generic-entry risk, but sterile injectable manufacturing limits the number of reliable competitors.
DMPA contraception has the strongest commercial base, while long-acting reversible contraceptives create sustained competitive pressure.
Estradiol cypionate is structurally disadvantaged against oral, transdermal, and vaginal estrogen products.
Public filings do not provide dependable standalone revenue figures for these legacy brands.
Future value would depend on differentiated delivery, self-administration, supply reliability, public-sector contracts, or regional licensing rather than core-molecule patents.

FAQs About Estradiol Cypionate and Medroxyprogesterone Acetate

Is estradiol cypionate still commercially available in the United States?

Estradiol cypionate has an established FDA-approved product history, but availability can depend on manufacturer production, distributor inventory, and pharmacy supply. Its market is substantially smaller than the markets for oral and transdermal estradiol.

Is medroxyprogesterone acetate the same as Depo-Provera?

Medroxyprogesterone acetate is the active ingredient in Depo-Provera. Depo-Provera refers to Pfizer’s branded injectable contraceptive product, while generic products contain the same active ingredient in equivalent or comparable presentations.

Can generic manufacturers substitute medroxyprogesterone acetate for Depo-Provera?

An FDA-approved generic may be therapeutically substitutable under applicable state pharmacy laws and product-specific rules. Injectable depot products require assessment of formulation, route, dose, and FDA equivalence requirements.

Does medroxyprogesterone acetate have biosimilar competition?

No. MPA is a chemically synthesized small molecule, not a biologic. Competition occurs through conventional generic-drug pathways rather than biosimilar applications.

Could a new estradiol cypionate and MPA combination create meaningful exclusivity?

A combination could receive patent protection or regulatory exclusivity if it included a novel formulation, delivery system, dosing regimen, or clinically differentiated use. A simple combination of two old active ingredients would face substantial patentability and obviousness challenges and would not automatically create durable market protection.

References

World Health Organization. (2022). Family planning: A global handbook for providers (4th ed.). World Health Organization and Johns Hopkins Bloomberg School of Public Health.
U.S. Food and Drug Administration. (2024). Depo-Provera CI: Medroxyprogesterone acetate injectable suspension prescribing information. Pfizer Laboratories.
U.S. Food and Drug Administration. (2024). Depo-subQ Provera 104: Medroxyprogesterone acetate injectable suspension prescribing information. Pfizer Laboratories.
U.S. Food and Drug Administration. (2023). Depo-Estradiol: Estradiol cypionate injection prescribing information. Pfizer Laboratories.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. Orange Book.
Pfizer Inc. (2024). 2023 annual report. Pfizer Inc.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	2
DailyMed Link:	ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE at DailyMed

Sponsor	Phase
Galeno Desenvolvimento de Pesquisas Clínicas	Phase 1
Biolab Sanus Farmaceutica	Phase 1
Sun Pharmaceutical Industries Limited	Phase 1/Phase 2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	LUNELLE	estradiol cypionate; medroxyprogesterone acetate	INJECTABLE;INTRAMUSCULAR	020874-001	Oct 5, 2000		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE - Generic Drug Details

What are the generic drug sources for estradiol cypionate; medroxyprogesterone acetate and what is the scope of patent protection?

Summary for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

Recent Clinical Trials for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

Anatomical Therapeutic Chemical (ATC) Classes for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

US Patents and Regulatory Information for ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

Estradiol Cypionate and Medroxyprogesterone Acetate: Market Dynamics, Patent Status, and Financial Trajectory